Unlocking a Novel Approach to Drug Discovery for Neurology


Biosensors will shed light on complicated neuron binding in the brain

Credit: Pixabay
Neurons Credit: Pixabay

Understanding our brain’s lock-and-key inhibitory actions may soon become considerably easier, thanks to the development of new molecular trackers by Kyoto University scientists.

In a study published in Nature Chemical Biology, the research team designed biosensors that can tag with GABAA receptors –a clinically relevant drug target — to trace their structural features and interactions with other molecules.

GABAA receptors, short for gamma-aminobutyric acid receptors, act as some sort of gateway channels in the brain that conduct ions when unlocked by the natural key GABA. The overall effect of this unlocking activity gives us a relaxed feeling as neurons are prevented from firing and becoming excited.

Investigating the binding activity of GABA receptors has been a major challenge because of the multiple binding sites and the non-specific manner with which they get unlocked. Researchers say the discovery of the molecular trackers could one day lead to the development of pharmaceuticals that can selectively treat various neurological disorders such as panic attacks, seizures, and Parkinson’s, with very little side effects.

The biosensors have proved to be useful for screening a wide chemical library that targets specific GABAA receptor sites. Testing with a large number of pharmaceutical compounds, the biosensors helped identify four hit molecules that are capable of interacting with GABAAreceptors.

“These semisynthetic biosensors represent versatile platforms for screening drugs to treat GABAA receptor-related neurological disorders,” say the authors.

Source: Kyoto University